Analysts’ Recent Ratings Changes for Kestra Medical Technologies (KMTS)

Several analysts have recently updated their ratings and price targets for Kestra Medical Technologies (NASDAQ: KMTS):

• 9/16/2026 – Kestra Medical Technologies was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 9/15/2026 – Kestra Medical Technologies was given a new $30.00 price target by Royal Bank Of Canada.
• 9/15/2026 – Kestra Medical Technologies had its “overweight” rating reaffirmed by Piper Sandler.
• 9/15/2026 – Kestra Medical Technologies had its “buy” rating reaffirmed by BTIG Research. They now have a $32.00 price target on the stock.
• 9/12/2026 – Kestra Medical Technologies was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/2/2026 – Kestra Medical Technologies had its “buy” rating reaffirmed by BTIG Research. They now have a $32.00 price target on the stock.
• 8/31/2026 – Kestra Medical Technologies was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/11/2026 – Kestra Medical Technologies was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/10/2026 – Kestra Medical Technologies is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $30.00 price target on the stock.
• 8/8/2026 – Kestra Medical Technologies was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Activity at Kestra Medical Technologies

In related news, Director Conor Hanley sold 5,694 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $25.25, for a total transaction of $143,773.50. Following the transaction, the director owned 6,272 shares in the company, valued at $158,368. The trade was a 47.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Raymond Cohen sold 3,330 shares of Kestra Medical Technologies stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $29.28, for a total transaction of $97,502.40. Following the completion of the sale, the director directly owned 54,790 shares of the company’s stock, valued at approximately $1,604,251.20. This trade represents a 5.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 246,928 shares of company stock worth $5,997,473. Corporate insiders own 5.30% of the company’s stock.

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies designed to help protect patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, or WCD, which is intended to provide temporary protection for patients who may be at elevated risk of life-threatening ventricular arrhythmias.

The ASSURE system continuously monitors a patient’s heart rhythm and is designed to detect potentially dangerous arrhythmias, including ventricular tachycardia and ventricular fibrillation.